Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity: A Feasibility Study of the Vigilant App (Vigilant-2)

Launched by MAYO CLINIC · Nov 4, 2024

Keywords

ClinConnect Summary

The Vigilant-2 study is exploring how a mobile app called Vigilant can help patients with skin cancer, specifically melanoma, keep track of their symptoms while receiving a type of treatment called immune checkpoint inhibitor therapy. This therapy uses medications like ipilimumab and nivolumab to help the body fight cancer. The goal of this study is to see if using this app can make it easier for patients to report any side effects they experience, which could help doctors manage these effects better.

To be eligible for the study, patients need to be starting this specific combination of therapies for their skin cancer. The study is open to all genders and is looking for participants aged 65 and older. If you decide to join, you can expect to use the app to monitor your health, share your experiences, and contribute to important research that may improve care for future patients. This study is currently recruiting participants, so it's a great opportunity to be involved in something that could help others facing similar challenges.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Any skin cancer/melanoma patient starting dual \[ipilimumab/nivolumab (IPI/NIVO)\] immune checkpoint inhibitor (ICI) therapy
• Exclusion Criteria:
• • Does not meet inclusion criteria